IAI FigSearch
Home Help [Feedback] [For Subscribers] [Archive] [Search] --
IAI Accepts, published online ahead of print on 30 October 2006
This Article
Right arrow Full Text (PDF)
Right arrow Other Versions of this Article:
IAI.00897-06v1
75/1/523    most recent
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ryan, A. A
Right arrow Articles by Triccas, J. A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ryan, A. A
Right arrow Articles by Triccas, J. A.

 Previous Article  |  Next Article 

Infect. Immun. doi:10.1128/IAI.00897-06
Copyright (c) 2006, American Society for Microbiology and/or the Listed Authors/Institutions. All Rights Reserved.

Secretion of functional Monocyte Chemotactic Protein-3 by recombinant Mycobacterium bovis BCG attenuates vaccine virulence and maintains protective efficacy against M. tuberculosis infection

Anthony A Ryan, Joanne M. Spratt, Warwick J. Britton, and James A. Triccas*

Mycobacterial Research Group, Centenary Institute of Cancer Medicine and Cell Biology, Locked Bag No. 6, Newtown, NSW 2042 Australia; Discipline of Medicine; Discipline of Infectious Diseases and Immunology, University of Sydney, NSW, 2006, Australia

* To whom correspondence should be addressed. Email: jamiet{at}infdis.usyd.edu.au.


   Abstract

A strain of Mycobacterium bovis BCG that secretes high levels of functional murine Monocyte Chemotactic Protein-3 (BCGMCP-3) was developed. Mice vaccinated with BCGMCP-3 displayed increased lymphocyte migration in vivo and augmented antigen-specific T cell responses compared to BCG alone. The level of protection afforded by BCGMCP-3 was equivalent to control BCG, however immunodeficient mice infected with BCGMCP-3 survived significantly longer than mice infected with the control BCG strain. Therefore BCGMCP-3 may be a safer alternative than conventional BCG for vaccination of immunocompromised individuals.




This article has been cited by other articles:




Home Help [Feedback] [For Subscribers] [Archive] [Search] --
J. Bacteriol. J. Virol. Eukaryot. Cell
Microbiol. Mol. Biol. Rev. Clin. Vaccine Immunol. All ASM Journals

Copyright © 2006 by the American Society for Microbiology. All rights reserved.